Skip to main content

11-12-2019 | Breast cancer | Video

SABCS 2019 | Adjuvant trastuzumab emtansine an option for certain early-stage breast cancer patients

Sara Tolaney takes us through the ATEMPT adjuvant therapy trial comparing trastuzumab emtansine with trastuzumab plus paclitaxel in patients with stage I HER2-positive breast cancer (4:01).

Funding for independent interviews at SABCS 2019 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits